{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
pantothenic acid
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Nolomirole (CHF1035) is an orally active, selective dopamine agonist, primarily activating DA2- and alpha2 receptors, thereby inhibiting norepinephrine release, which may be beneficial in heart failure. Nolomirole is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure. CHF1035 is a mixture of two enantiomers, CHF1800 (+) and CHF1810 (-). CHF1035 and its metabolite CHF1024 significantly decreased the IOP in rabbits, and are potential novel IOP lowering agents. Especially, CHF1035 produced a substantial decrease in IOP for a prolonged period of time, and thus may prove useful in glaucoma therapy. Nolomirole is a pre-synaptic stimulator of DA2-dopaminergic and α2-adrenergic receptors in peripheral sympathetic nerve endings. These receptors act as a negative feedback mechanism, inhibiting norepinephrine secretion. In early phase clinical studies lasting 1–3 months, nolomirole reduced peripheral systemic resistance and 24 hour blood pressure and increased cardiac output. In a study of 29 patients with heart failure, followed for 10 days, a reduction in plasma norepinephrine was demonstrated. In spite of the fact that Nolomirole was in clinical trials for the treatment of heart failure, its development was discontinued.
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Proadifen is an inhibitor of drug metabolism and cytochrome P450 enzyme system activity. It stimulated the release of prostacyclin (PGI2) from the rabbit aorta, bovine aorta and human umbilical vein in vitro, but had no effect on cultured smooth muscle from the bovine aortic media. In human platelets, proadifen inhibited prostaglandin and thromboxane production induced by A23187, thrombin, and ADP. Proadifen might thus constitute the prototype of a new class of antiplatelet drugs.
Status:
Investigational
Source:
NCT01877694: Phase 2 Interventional Completed Bacterial Conjunctivitis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Auriclosene (previously known as NVC-422) is a broad-spectrum, fast-acting topical anti-infective agent against microbial pathogens, including antibiotic-resistant microbes. It has been investigated in phase II clinical trials for the treatment of bacterial conjunctivitis and as a topical gel in children with impetigo. In addition, using a guinea pig model was shown, that auriclosene was effective in the treatment of dermatophytosis, including onychomycosis.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Hydroxytoluic acid is a long-acting derivative of salicylate with antilipidemic properties. It shows fibrinolytic activity in human plasma by activating the fibrinolytic system and has been shown to lower plasma free fatty acid, cholesterol levels, and to raise metabolic oxygen consumption.
Class (Stereo):
CHEMICAL (ACHIRAL)
Enoxamast (PRH-836-EA) is a N-(4-substituted-thiazolyl)oxamic acid derivative with antiallergic activity.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifuroquine is an antibacterial agent, used in the treatment of bovine mastitis.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Butaprost, a structural analog of PGE2, is a selective agonist for the EP2 receptor subtype. EP2 receptors are expressed on human neutrophils and on respiratory, vascular, and uterine smooth muscle. Butaprost binds with about 1/10 the affinity of PGE2 to the recombinant murine EP2 receptor and does not bind appreciably to the other murine EP receptors or the DP, TP, FP, and IP receptors. Butaprost has frequently been used to pharmacologically define the EP receptor expression profile of various human and animal tissues and cells. Butaprost effectively reduces the subconjunctival scarring response. Given the significance of wound healing modulation in blebs, butaprost's inhibitory effect on subconjunctival Tenon's fibroblasts may be beneficial in managing postoperative scarring in glaucoma surgery.
Status:
Investigational
Source:
INN:valdipromide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Valdipromide is an antidepressant.
Status:
Investigational
Source:
NCT00703573: Phase 2 Interventional Completed Atopic Dermatitis
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Shionogi developed S 777469 as a selective cannabinoid 2 receptor agonist for the atopic dermatitis treatment. This drug successfully completed phase II clinical trial, where was evaluate its safety and efficacy in patients with atopic dermatitis. However, information about the further development of S 777469 is not available.
